FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
Lei Lei Wu / endpoints - The FDA has approved the TROP2-directed antibody-drug conjugate Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead. The approval marks Datroway’s third, after ...
AI Summary: Daiichi Sankyo and AstraZeneca’s breast cancer therapy Datroway has cleared key regulatory hurdles, winning FDA approval and earning backing from European regulators. The approvals validate pivotal trial results and pave the way for clinical adoption in the indicated patient population, prompting clinicians to prepare for integration into treatment pathways and health systems to weigh formulary and access decisions.
- Clinicians weigh Datroway’s role in TNBC care (3)
- FDA win and market stakes for Datroway (3)
- All Other Stories
Clinicians weigh Datroway’s role in TNBC care
FDA win and market stakes for Datroway
All Other Stories
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days
BeOne’s BCL2 inhibitor gains FDA approval challenging Venclexta / 15 days
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 20 days
FDA grants early access to experimental pancreatic cancer drug / 29 days
FDA approves relacorilant plus nab‑paclitaxel for resistant ovarian cancers / 7 wks
FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Food Safety, Rural Health, Pharmaceuticals and look for the RSS link.
StackHealth Time Machine